LTBP-2 acts as a novel marker in human heart failure a preliminary study

Biomarkers

Volumn 17, Issue 5, 2012, Pages 407-415

  Bai, Yuanyuan ^a   Zhang, Peng ^a   Zhang, Xiaoling ^a   Huang, Jie ^a   Hu, Shengshou ^a   Wei, Yingjie ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Biomarker; Heart failure; Heart failure with reduced ejection fraction; Latent TGF binding protein 2 (LTBP 2); Signaling pathway

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 2; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DYSPNEA; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEWBORN; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; ANIMALS; ANIMALS, NEWBORN; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEART; HEART FAILURE; HUMANS; IMMUNOHISTOCHEMISTRY; LATENT TGF-BETA BINDING PROTEINS; MALE; MIDDLE AGED; MYOCYTES, CARDIAC; PROGNOSIS; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; STROKE VOLUME; TRANSFORMING GROWTH FACTOR BETA1;

RATTUS;

EID: 84864585401     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.677860     Document Type: Article

References (28)

1. Ahmed W, Kucich U, Abrams W, Bashir M, Rosenbloom J, Segade F, Mecham R, Rosenbloom J. (1998). Signaling pathway by which TGF-β1 increases expression of latent TGF-β binding protein-2 at the transcriptional level. Connect Tissue es 37:263-276.
2. Bilchick KC, Saha SK, Mikolajczyk E, Cope L, Ferguson WJ, Yu W, Girouard S, Kass DA. (2006). Differential regional gene expression from cardiac dyssynchrony induced by chronic right ventricular free wall pacing in the mouse. Physiol Genomics 26:109-115.
3. Breidthardt T, Potocki M, Vanpoucke G, Gregoire T, Laroy W, Verleysen K, Drexler B, Mebazaa A, Kas K, Mueller CH. (2011). The novel marker Ltbp2 powerfully predicts all-cause and pulmonary death in patients with acute dyspnea. Eur J Heart Fail 10:S112.
4. Bujak M, Frangogiannis NG. (2007). The role of TGF-β signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74:184-195.
5. Chen AA, Wood MJ, Krauser DG, Baggish AL, Tung R, Anwaruddin S, Picard MH, Januzzi JL. (2006). NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: Results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur. Heart J 27:839-845.
6. Cui C, Shi Q, Zhang X, Liu X, Bai Y, Li J, Liu S, Hu S, Wei Y. (2012). CRP promotes MMP-10 expression via c-Raf/MEK/ERK and JAK1/ ERK pathways in cardiomyocytes. Cell Signal 24:810-818.
7. Gabrielsen A, Lawler PR, Yongzhong W, Steinbrhel D, Blagoja D, Paulsson-Berne G, Kastrup J, Hansson GK. (2007). Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium. J Mol Cell Cardiol 42:870-883.
8. Hirani R, Hanssen E, Gibson MA. (2007). LTBP-2 specifically interacts with the amino-terminal region of fibrillin-1 and competes with LTBP-1 for binding to this microfibrillar rotein. Matrix Biol 26:213-223.
9. Hyytinen M, Keski-Oja J. (2003). Latent TGF-β binding protein LTBP-2 decreases fibroblast adhesion to fibronectin. J Cell Biol 163:1363-1374.
10. Jeyaseelan R, Poizat C, Baker RK, Abdishoo S, Isterabadi LB, Lyons GE, Kedes L. (1997). A novel cardiac-restricted target for doxorubicin. CARP, a nuclear modulator of gene expression in cardiac progenitor cells and cardiomyocytes. J Biol Chem 272:22800-22808.
11. Lok DJ, Van Der Meer P, de La Porte PW, Lipsic E, Van Wijngaarden J, Hillege HL, Van Veldhuisen DJ. (2010). Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin Res Cardiol 99:323-328.
12. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Murphy NF, Conlon C, Patle A, Donnelly SC, McDonald K. (2009). Diagnosis of heart failure with preserved ejection fraction: Improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail 11:191-197.
13. Massaous J, Hata A. (1997). TGF-β signalling through the Smad pathway. Trends Cell Biol 7:187-192.
14. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ. (2004). NT-proBNP and the diagnosis of heart failure: A pooled analysis of three European epidemiological studies. Eur J Heart Fail 6:269-273.
15. Michel K, Roth S, Trautwein C, Gong W, Flemming P, Gressner AM. (1998). Analysis of the expression pattern of the latent transforming growth factor β binding protein isoforms in normal and diseased human liver reveals a new splice variant missing the proteinase-sensitive hinge region. Hepatology 27:1592-1599.
16. Milting H, Ellinghaus P, Seewald M, Cakar H, Bohms B, Kassner A, Kfer R, Klein M, Krahn T, Kruska L, El Banayosy A, Kramer F. (2008). Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. J Heart Lung Transplant 27:589-596.
17. Miyazono K, Hellman U, Wernstedt C, Heldin CH. (1988). Latent high molecular weight complex of transforming growth factor β 1. Purification from human platelets and structural characterization. J Biol Chem 263:6407-6415.
18. Mor A, Olofsson A, Stenman G, Sahlin P, Kanzaki T, Claesson-Welsh L, ten Dijke P, Miyazono K, Heldin CH. (1994). Identification and characterization of LTBP-2, a novel latent transforming growth factor-β-binding protein. J Biol Chem 269:32469-32478.
19. OklR, Hesketh R. (2000). The latent transforming growth factor β binding protein (LTBP) family. Biochem J 352 Pt 3:601-610.
20. Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. (2006). Controversies in ventricular remodelling. Lancet 367:356-367.
21. Remme WJ, Swedberg K; European Society of Cardiology. (2002). Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 4:11-22.
22. Seeland U, Selejan S, Engelhardt S, Mler P, Lohse MJ, Bm M. (2007). Interstitial remodeling in β1-Adrenergic receptor transgenic mice. Basic Res Cardiol 102:183-93.
23. Shipley JM, Mecham RP, Maus E, Bonadio J, Rosenbloom J, McCarthy RT, Baumann ML, Frankfater C, Segade F, Shapiro SD. (2000). Developmental expression of latent transforming growth factor β binding protein 2 and its requirement early in mouse development. Mol Cell Biol 20:4879-4887.
24. Sinha S, Heagerty AM, Shuttleworth CA, Kielty CM. (2002). Expression of latent TGF-β binding proteins and association with TGF-β 1 and fibrillin-1 following arterial injury. Cardiovasc Res 53:971-983.
25. Taipale J, Saharinen J, Hedman K, Keski-Oja J. (1996). Latent transforming growth factor-β 1 and its binding protein are components of extracellular matrix microfibrils. J Histochem Cytochem 44:875-889.
26. Taub PR, Gabbai-Saldate P, Maisel A. (2010). Biomarkers of heart failure. Congest Heart Fail 16 Suppl 1:S19-S24.
27. Wei YJ, Huang YX, Zhang XL, Li J, Huang J, Zhang H, Hu SS. (2008). Apolipoprotein D as a novel marker in human end-stage heart failure: A preliminary study. Biomarkers 13:535-548.
28. Wei Y, Cui C, Lainscak M, Zhang X, Li J, Huang J, Zhang H, Zheng Z, Hu S. (2011). Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: Relationship between MMP-10 and LV remodelling. J Cell Mol Med 15:773-782.